IFN free regimens consisting of SOF and the second generation PI Simeprevir (SMV) or a NS5A-inhibitor like daclatasvir (DCV) or ledipasvir (LDV) for a fixed, predetermined duration of 8 to 24 weeks have been shown to be highly effective also without the usage of RBV and even in patients with liver cirrhosis and a previous null response to Peg-IFN/RBV [34]–[38]. Here, IFNA1 is linked to cirrhosis of liver.